Understanding the genetic factors of neurofibromatosis and finding new treatment options
Elucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targets
This study is looking at how changes in the NF2 gene cause tumors in people with neurofibromatosis type 2 (NF2) and is exploring new ways to slow down tumor growth to help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-10912701 on NIH RePORTER |
What this research studies
This research investigates neurofibromatosis type 2 (NF2), a genetic disorder that leads to the formation of tumors called schwannomas. The study focuses on understanding how mutations in the NF2 gene affect tumor growth and exploring potential therapeutic targets. Researchers are using advanced techniques to analyze the epigenetic landscape of NF2-deficient tumors and assess the effectiveness of specific inhibitors that may slow down tumor growth. By identifying vulnerabilities in these tumors, the research aims to develop new treatment strategies for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with neurofibromatosis type 2 or those with related tumors caused by NF2 mutations.
Not a fit: Patients without neurofibromatosis type 2 or those whose tumors are not related to NF2 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively treat neurofibromatosis type 2 and related tumors.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other tumor types, suggesting that this approach may be effective for NF2-related tumors as well.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Kissil, Joseph — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Kissil, Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.